RegoNivo vs Standard of Care Chemotherapy in AGOC
Phase 3
Completed
NCT04879368
| Condition | Gastro-Oesophageal Cancer |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Australasian Gastro-Intestinal Trials Group |
|---|
| Status | Completed |
|---|
| Enrollment | 462 participants |
|---|
| Interventions | Regorafenib, Nivolumab, Docetaxel, Paclitaxel, Irinotecan |
|---|
| Start date | May 5, 2021 |
|---|
| Completion date | Jan 14, 2025 |
|---|
| Results posted | Jun 10, 2026 |
|---|
Summary
To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC.
O/S
From the date of randomisation to date of death from any cause or the date last known alive, assessed up to approximately 44 months. · Months
| RegoNivo | 5.91 Months |
|---|
| Standard of Care | 6.28 Months |
|---|
| p-value | 0.23 |
|---|
| Hazard Ratio (HR) | 0.88 (95% CI 0.71–1.09) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.